Organic cation transporter 6 directly confers resistance to anticancer platinum drugs

Oguri,Tetsuya; Kunii,Eiji; Fukuda,Satoshi; Sone,Kazuki; Uemura,Takehiro; Takakuwa,Osamu; Kanemitsu,Yoshihiro; Ohkubo,Hirotsugu; Takemura,Masaya; Maeno,Ken; Ito,Yutaka; Niimi,Akio

doi:10.3892/br.2016.772

Organic cation transporter 6 directly confers resistance to anticancer platinum drugs

Authors:
- Tetsuya Oguri
- Eiji Kunii
- Satoshi Fukuda
- Kazuki Sone
- Takehiro Uemura
- Osamu Takakuwa
- Yoshihiro Kanemitsu
- Hirotsugu Ohkubo
- Masaya Takemura
- Ken Maeno
- Yutaka Ito
- Akio Niimi
View Affiliations

Affiliations: Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467‑8601, Japan
Published online on: October 4, 2016 https://doi.org/10.3892/br.2016.772
Pages: 639-643

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Organic cation transporters (OCTs) of the solute carrier family 22 have a critical role in the cellular uptake of anticancer platinum drugs. Recently, we found that a decreased OCT6 expression is associated with a reduced intracellular uptake of cisplatin (CDDP), and concomitant resistance to CDDP. In the present study, we examined whether OCTs directly confer resistance to another platinum drug, oxaliplatin (L‑OHP). To address this, we used parental lung cancer cell lines, PC‑14 and SBC3; L‑OHP‑resistant sublines, PC‑14/L‑OHP and SBC3/L‑OHP; and one CDDP‑resistant subline PC‑14/CDDP, to examine the relationships between the expression of OCTs and intracellular platinum drug concentration or platinum drug resistance. The two L‑OHP-resistant sublines showed cross resistance to CDDP and L‑OHP, and a decreased expression of OCT6. The intracellular accumulation of L‑OHP in PC‑14/L‑OHP cells was reduced compared with the parental cells. The findings suggested that a reduced OCT6 expression confers platinum drug resistance in the sublines by decreasing the uptake of platinum drugs. Using the PC‑14/CDDP cell line engineered to overexpress OCT6, we confirmed that the intracellular L‑OHP concentration was increased concomitantly with OCT6 overexpression compared with the parental cell line. Additionally, OCT6 was expressed in a screening panel of lung and colon cancer tissues and matched normal control tissues. Taken together with the previous results, the present findings indicate that OCT6 is directly involved in platinum drug resistance by mediating platinum drug uptake in cancer cells.

View Figures

View References

1	Sculier JP, Berghmans T and Meert AP: Advances in target therapy in lung cancer. Eur Respir Rev. 24:23–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Heinemann V, Douillard JY, Ducreux M and Peeters M: Targeted therapy in metastatic colorectal cancer - an example of personalised medicine in action. Cancer Treat Rev. 39:592–601. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584. 2007. View Article : Google Scholar : PubMed/NCBI
4	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
5	Oguri T, Fujiwara Y, Isobe T, Katoh O, Watanabe H and Yamakido M: Expression of γ-glutamylcysteine synthetase (γ-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs. Br J Cancer. 77:1089–1096. 1998. View Article : Google Scholar : PubMed/NCBI
6	Oguri T, Fujiwara Y, Miyazaki M, Takahashi T, Kurata T, Yokozaki M, Ohashi N, Isobe T, Katoh O and Yamakido M: Induction of γ-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients. Ann Oncol. 10:455–460. 1999. View Article : Google Scholar : PubMed/NCBI
7	Oguri T, Isobe T, Suzuki T, Nishio K, Fujiwara Y, Katoh O and Yamakido M: Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int J Cancer. 86:95–100. 2000. View Article : Google Scholar : PubMed/NCBI
8	Oguri T, Isobe T, Fujitaka K, Ishikawa N and Kohno N: Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer. 93:584–589. 2001. View Article : Google Scholar : PubMed/NCBI
9	Koepsell H, Lips K and Volk C: Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 24:1227–1251. 2007. View Article : Google Scholar : PubMed/NCBI
10	Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, et al: Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 66:8847–8857. 2006. View Article : Google Scholar : PubMed/NCBI
11	Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J and Schlatter E: Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 167:1477–1484. 2005. View Article : Google Scholar : PubMed/NCBI
12	Kunii E, Oguri T, Kasai D, Ozasa H, Uemura T, Takakuwa O, Ohkubo H, Takemura M, Maeno K and Niimi A: Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer. Cancer Chemother Pharmacol. 75:985–991. 2015. View Article : Google Scholar : PubMed/NCBI
13	Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ and Siddik ZH: Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol. 30:3345–3352. 2012. View Article : Google Scholar : PubMed/NCBI
14	Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T and Inui K: Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol. 74:477–487. 2007. View Article : Google Scholar : PubMed/NCBI
15	Yonezawa A and Inui K: Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol. 81:563–568. 2011. View Article : Google Scholar : PubMed/NCBI
16	Tashiro A, Tatsumi S, Takeda R, Naka A, Matsuoka H, Hashimoto Y, Hatta K, Maeda K and Kamoshida S: High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy. Am J Cancer Res. 4:528–536. 2014.PubMed/NCBI
17	Naka A, Takeda R, Shintani M, Ogane N, Kameda Y, Aoyama T, Yoshikawa T and Kamoshida S and Kamoshida S: Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer. Am J Cancer Res. 5:2285–2293. 2015.PubMed/NCBI
18	Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T, Mizoi T, Shiiba K, Takanaga H, Terasaki T, et al: Characterization of the organic cation transporter SLC22A16: A doxorubicin importer. Biochem Biophys Res Commun. 333:754–762. 2005. View Article : Google Scholar : PubMed/NCBI
19	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 26:1877–1883. 2015. View Article : Google Scholar : PubMed/NCBI
20	Gong S, Lu X, Xu Y, Swiderski CF, Jordan CT and Moscow JA: Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp Hematol. 30:1162–1169. 2002. View Article : Google Scholar : PubMed/NCBI
21	Minematsu T and Giacomini KM: Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther. 10:531–539. 2011. View Article : Google Scholar : PubMed/NCBI